Full-Time

Medical Quality Manager

India

Posted on 10/31/2025

Deadline 11/14/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Mumbai, Maharashtra, India

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Educational background: Scientific or technical degree preferred (BS or MS) with over 3 years of experience in compliance/SOP management, auditing, QA/QC, or related field
  • Understanding of the local promotional compliance environment
  • Appreciation of the compliance issues relating to the local medical function
  • Experience in a matrixed organization is valued
Responsibilities
  • Drive Level 1 medical quality oversight and business support at the market level
  • Lead the development of country medical quality strategic initiatives based on risk and business needs, in close collaboration with local medical management, IMQ, and other key stakeholders (e.g., Platform Line management [Safety, Regulatory])
  • Execute Global Quality Plans. Develop and maintain Country Operational Plans as applicable
  • Demonstrate MQ value proposition to internal stakeholders and external customers
  • Lead continuous medical inspection readiness efforts in collaboration with applicable global inspections management teams, Business Units, and Platform Line representatives
  • Communicate relevant audit and inspection trends to respective country stakeholders, ensure that applicable actions are taken to address country gaps
  • Develop and maintain the in-country Regulatory Inspection Site Notification Plan
  • Coordinate Regulatory Quality Assurance Pfizer Country Organization (PCO) audits and vendor audits (vendor audits if in IMQ remit, depending on scope), including management of audit CAPAs
  • Support Corporate Audit requests within scope of IMQ as appropriate
  • Support external inspections as appropriate in partnership with global inspection management teams
  • Support maintenance of professional records for Medical Affairs colleagues
  • Drive effective management of quality events (QE) and CAPAs for PCO scoped QEs within MQM remit and act as the Business Line Quality Group role
  • Monitor and drive PCO QEs and CAPA performance
  • Act as local QMS01 expert and build PCO awareness on issue escalation & remediation requirements in partnership with other quality lines
  • Develop or support the development, implementation, and maintenance of in-country controlled documents within the scope of QMS04 and within MQM remit in collaboration with relevant Subject Matter Experts (SME)
  • Act as local expert on QMS04 and ensure local controlled clinical and medical documents within MQM remit follow applicable Pfizer policies and procedures and regulatory requirements
  • Facilitate local implementation of global Standard Operating Procedures (SOPs) and ensure relevant communication is cascaded accordingly
  • Provide input to draft Global SOPs, Policies, Work Instructions (WI) and related training materials offering the country perspective and local impact
  • Support the process for impact assessment of new or revised regulatory requirements and legislation impacting the medical Quality Management System (QMS)
  • Ensure local training requirements in MQM remit are included in the appropriate curricula
  • Ensure local curricula in MQM remit are maintained in line with Pfizer standards
  • Facilitate local training compliance reporting for in-country Medical Affairs where needed
  • Act as a local Expert on QMS07 and Pfizer’s Global Learning Management System
  • In collaboration with local management, identify additional training needs on quality related areas (in addition to MEL mandatory requirements); facilitate, support, conduct of additional training for identified areas
  • Identify local areas for monitoring (e.g. via quality reviews) in collaboration with in-country medical management and IMQ as appropriate
  • Execute monitoring activities as defined by applicable global quality plans
Desired Qualifications
  • Fluency in English
  • Expertise in managing multiple complex projects
  • Ability to work independently
  • Able to lead without reporting line authority at senior level
  • Project Management expertise
  • Excellent verbal, written, and presentation skills
  • Collaboration, interpersonal and facilitation skills
  • Continuous Improvement and/ or organizational effectiveness expertise
  • Display sensitivity to manage relationships and ability to build collaborative working relationships with colleagues and associates both within and external to the organization
  • Collaborate efficiently across functional and country boundaries, respecting communication, functional priorities, and cultural differences in interpersonal relationships

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE